Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 5:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 3,139 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: placebo solution Clear all
Suspended Phase 2Phase 3 Interventional

Efficacy and Safety of RPH-104 Treatment in Patients With Recurrent Pericarditis

NCT05107934
View directory record Official record
Conditions
Recurrent Pericarditis
Interventions
RPH-104, Placebo
Biological · Drug
Lead sponsor
R-Pharm Overseas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 15, 2024 · Synced Oct 24, 2026, 5:39 PM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence

NCT01767519
View directory record Official record
Conditions
Overactive Bladder, Urinary Incontinence
Interventions
BOTOX®, solifenacin, Botox placebo (normal saline), solifenacin placebo
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 24, 2026, 5:39 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

NCT05809934
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
AZD2693, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
37
States / cities
Chandler, Arizona • Peoria, Arizona • Surprise, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Oct 24, 2026, 5:39 PM EDT
Recruiting Phase 1 Interventional

The Effects and Mechanisms of a High CBD Cannabis Extract (BRC-002) for the Treatment of Pain and Health in Complex Regional Pain Syndrome

NCT06393101
View directory record Official record
Conditions
Complex Regional Pain Syndrome
Interventions
BRC-002, BRC-002 Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
21 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
La Jolla, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2024 · Synced Oct 24, 2026, 5:39 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Investigating the Wrinkle Reduction Potential of a Novel Compounded Skin Care Cream

NCT03878381
View directory record Official record
Conditions
Skin Care
Interventions
Skin Care Cream, Placebo
Combination Product · Drug
Lead sponsor
Wayne State University
Other
Eligibility
20 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Dearborn, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Oct 24, 2026, 5:39 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Pilot Study: Rectus Sheath Blocks for Improving Abdominal Surgery Conditions

NCT02447965
View directory record Official record
Conditions
Hernia, Pain, Postoperative, Abdominal Wall Relaxation After Rectus Sheath Block
Interventions
Bupivacaine, Normal Saline
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 24, 2026, 5:39 PM EDT
Terminated Phase 3 Interventional Results available

Initiating Ketamine in Acutely Suicidal Patients in the Emergency Department

NCT04260607
View directory record Official record
Conditions
Suicide, Suicide Threat, Depression Severe
Interventions
Ketamine Hydrochloride, Normal saline
Drug
Lead sponsor
Naval Medical Center Camp Lejeune
Federal
Eligibility
18 Years to 89 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Marine Corps Base Camp Lejeune, North Carolina
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Oct 24, 2026, 5:39 PM EDT
Recruiting Phase 3 Interventional

Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke

NCT05691244
View directory record Official record
Conditions
Acute Ischemic Stroke, Cerebral Stroke
Interventions
Drug: Normal Saline, Sovateltide
Drug
Lead sponsor
Pharmazz, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
14
States / cities
Tucson, Arizona • Carmichael, California • Oxnard, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 24, 2026, 5:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of Lu AG06474 in Healthy Young Men

NCT05003687
View directory record Official record
Conditions
Healthy
Interventions
Lu AG06474, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 9, 2023 · Synced Oct 24, 2026, 5:39 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke

NCT01464307
View directory record Official record
Conditions
Post-stroke Spasticity of the Lower Limb
Interventions
IncobotulinumtoxinA (400 Units), Placebo Comparator
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years to 80 Years
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
12
States / cities
Downey, California • Long Beach, California • Fairfield, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2016 · Synced Oct 24, 2026, 5:39 PM EDT
Completed Phase 2 Interventional Results available

PECS Block vs. Multimodal Analgesia for Prevention of Persistent Postoperative Pain in Breast Surgery

NCT03084536
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Female, Cancer of Breast
Interventions
Bupivacaine, Gabapentin, Celecoxib, Acetaminophen, Midazolam, Fentanyl
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 24, 2024 · Synced Oct 24, 2026, 5:39 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-threatening Influenza

NCT00453999
View directory record Official record
Conditions
Influenza
Interventions
Peramivir 200 mg, Peramivir 400 mg, Oseltamivir
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
41
States / cities
Mobile, Alabama • Jonesboro, Arkansas • Orange, California + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2015 · Synced Oct 24, 2026, 5:39 PM EDT
Completed Phase 2 Interventional Results available

LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)

NCT04402957
View directory record Official record
Conditions
COVID, Severe Acute Respiratory Syndrome, Sars-CoV2, Acute Kidney Injury, Acute Respiratory Distress Syndrome
Interventions
LSALT peptide, Placebo
Drug
Lead sponsor
Arch Biopartners Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
San Diego, California • Fort Lauderdale, Florida • Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Oct 24, 2026, 5:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose (BMS-813160) Study

NCT01049165
View directory record Official record
Conditions
Accelerated Intimal Hyperplasia
Interventions
BMS-813160, [14C] BMS-813160, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 11, 2011 · Synced Oct 24, 2026, 5:39 PM EDT
Completed Phase 3 Interventional Results available

Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)

NCT03036488
View directory record Official record
Conditions
Triple Negative Breast Neoplasms
Interventions
Pembrolizumab, Carboplatin, Paclitaxel, Doxorubicin, Epirubicin, Cyclophosphamide, Placebo, Granulocyte colony stimulating factor: Filgrastim or Pegfilgrastim
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
47
States / cities
Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 38 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 24, 2026, 5:39 PM EDT
Completed Not applicable Interventional Results available

The Effects of Dexamethasone on the Time to Pain Resolution in Dental Periapical Abscess

NCT03005522
View directory record Official record
Conditions
Dental Research, Pharmaceutical Preparations, Dental
Interventions
oral dexamethasone, Placebo Oral Capsule
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 28, 2022 · Synced Oct 24, 2026, 5:39 PM EDT
Completed Phase 2 Interventional Results available

COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Master Protocol

NCT04662086
View directory record Official record
Conditions
Covid19
Interventions
Acebilustat, Camostat
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Pleasanton, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 24, 2026, 5:39 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Intranasal Vasopressin Treatment in Children With Autism

NCT03204786
View directory record Official record
Conditions
Autism, Autism Spectrum Disorder, ASD
Interventions
Vasopressin (USP) Injectable Solution [Vasostrict], Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
6 Years to 17 Years
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 24, 2026, 5:39 PM EDT
Active, not recruiting Early Phase 1 Interventional

Efficacy of Spinal Manipulation Therapy or Mindfulness-based Reduction Therapy on Patients With Chronic Low Back Pain

NCT04744883
View directory record Official record
Conditions
Chronic Low-back Pain
Interventions
Spinal Manipulation Therapy (SMT), Naloxone, Placebo, Mindfulness Based Stress Reduction Therapy (MT)
Other · Drug · Behavioral
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
Chicago, Illinois • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Oct 24, 2026, 5:39 PM EDT
Terminated Phase 3 Interventional Results available

A Phase III Efficacy and Safety Study of Intravenous Retosiban Versus Placebo for Women in Spontaneous Preterm Labor

NCT02377466
View directory record Official record
Conditions
Obstetric Labour, Premature
Interventions
Retosiban IV infusion, Placebo IV infusion
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 45 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
33
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Oct 24, 2026, 5:39 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.

NCT03715153
View directory record Official record
Conditions
Autism Spectrum Disorder (ASD)
Interventions
BUMETANIDE (S95008) for week 0 - 26, PLACEBO for week 0 - 26, Open-Label BUMETANIDE (S95008) for weeks 26 - 52
Drug
Lead sponsor
Institut de Recherches Internationales Servier
Other
Eligibility
2 Years to 6 Years
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Staten Island, New York
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Oct 24, 2026, 5:39 PM EDT
Completed Early Phase 1 Interventional Results available

Topical Tranexamic Acid Use on Granulating Wounds Following Mohs Micrographic Surgery

NCT04541303
View directory record Official record
Conditions
Postoperative Wound Haemorrhage
Interventions
Tranexamic acid, normal saline
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Oct 24, 2026, 5:39 PM EDT
Completed Phase 1 Interventional

Study of ST266 Eye Drops in Treating Dry Eye

NCT02369861
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
ST266, Refresh Lubricant Eye Drops
Drug
Lead sponsor
Noveome Biotherapeutics, formerly Stemnion
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 13, 2019 · Synced Oct 24, 2026, 5:39 PM EDT
Terminated Phase 3 Interventional Results available

Fluorescence Imaging of Carcinoma During Breast Conserving Surgery

NCT04815083
View directory record Official record
Conditions
Breast Neoplasm Female, Breast Cancer
Interventions
Aminolevulinic Acid Hydrochloride, Eagle V1.2 Imaging System, Placebo
Drug · Device
Lead sponsor
SBI ALApharma Canada, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
7
States / cities
Stamford, Connecticut • Clearwater, Florida • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Oct 24, 2026, 5:39 PM EDT